About 30 minutes
Source-reported half-life, not independently established in a dedicated trial.
Protocol / Research Dosing Guide
CJC-1295 without DAC Guide: Community Schedule and Safety
An evidence-organized Mod GRF(1-29) reference that does not transfer long-acting DAC study results to the short-acting molecule.
Last reviewed September 15, 202620 minute readResearch information only
Level 1 — No direct human protocol trialsShort-acting GHRH analogueNot FDA approved
CJC-1295 without DAC Quick Start
CJC-1295 without DAC is a short-acting modified GHRH fragment commonly called Mod GRF(1-29). Human findings from the albumin-binding DAC molecule cannot be assigned to this form.
Why researchers care
Pulsatile growth-hormone research
Class
Tetrasubstituted GRF(1-29), also called Mod GRF(1-29)
Route reported
Subcutaneous use is community reported
Cycle length
Community cycles reported; not validated
Regulatory status
Research-use listing; not FDA approved
Loading supplier information
CJC-1295 without DAC Dosing Protocol and Schedule
The supplied source reports 100–300 mcg per injection from once to three times daily. No direct human dose-finding trial validates those amounts, timing rules, or cycles.
| Phase or study | Amount | Frequency / evidence |
|---|---|---|
| Weeks 1–2 | 100 mcg once daily | Community reported |
| Weeks 3–4 | 150 mcg once daily | Community reported |
| Weeks 5–8 | 200 mcg once daily | Community reported |
| Weeks 5–12+ | 200–300 mcg once or twice daily | Community reported |
The reported five-days-on/two-days-off and four-to-twelve-week cycles are community conventions, not clinical findings.
CJC-1295 without DAC Supplies Needed
Neutral research-material planning only. This does not establish an appropriate amount or route.
Research planning item
Exact labeled research vial
Research planning item
Measured diluent volume
Research planning item
U-100 measurement reference
Research planning item
Alcohol swabs
Research planning item
Appropriate sharps container
Research planning item
Written concentration label
CJC-1295 without DAC Reconstitution Calculator
Vial-format concentration math
Concentration
3.333 mg/mL
Draw volume
0.03 mL
U-100 units
3
Mathematical draws
100
Arithmetic only. The entered amount is not a recommendation and does not establish suitability.
Best Time to Take CJC-1295 without DAC: Morning or Night?
Fasted timing
The source emphasizes fasted windows; this is not validated in a direct human trial.
Pre-sleep timing
Community reported, not clinically established.
Frequency
One to three times daily is community reported.
Missed amount
No validated replacement procedure exists.
CJC-1295 without DAC Route Comparison
| Route | Evidence context | Boundary |
|---|---|---|
| Subcutaneous | Community use | No direct human protocol trial |
| Oral or nasal | Not established | No validated exposure |
| With-DAC form | Different albumin-binding molecule | PK cannot transfer |
| Blend with Ipamorelin | Separate fixed mixture | No blend trial |
Routes and amounts are not interchangeable unless a verified study explicitly establishes a conversion.
CJC-1295 without DAC Half-Life and Dosing Frequency
| Measure | Finding | Evidence limit |
|---|---|---|
| Reported half-life | Approximately 30 minutes | Secondary/source-reported |
| Direct human PK | Not established | No dedicated study located |
| GH pulse duration | Not established for this product | Do not infer from DAC form |
| Frequency | Community reported | Not trial derived |
CJC-1295 without DAC Dosage Chart
| Route | Amount | Frequency | Source | Human validation |
|---|---|---|---|---|
| Subcutaneous | 100 mcg | Once daily | Community report | No |
| Subcutaneous | 150 mcg | Once daily | Community report | No |
| Subcutaneous | 200 mcg | Once or twice daily | Community report | No |
| Subcutaneous | 300 mcg | Up to three times daily | Community report | No |
Published study values describe those studies. Community-reported values are not validated dosing recommendations.
CJC-1295 without DAC Reconstitution Guide
Concentration: 3.333 mg/mL
| Entered amount | Volume | U-100 units |
|---|---|---|
| 0.1 mg | 0.03 mL | 3 units |
| 0.2 mg | 0.06 mL | 6 units |
| 0.3 mg | 0.09 mL | 9 units |
- 1.Confirm the exact vial label and total quantity.
- 2.Record the measured diluent volume.
- 3.Clean the vial stopper.
- 4.Add liquid slowly along the vial wall.
- 5.Swirl gently; do not shake.
- 6.Inspect for cloudiness, discoloration, or particles.
- 7.Label the calculated concentration and preparation date.
- 8.Use the result only for arithmetic, not as a recommendation.
Reconstitution does not establish identity, purity, sterility, stability, or an appropriate amount.
How CJC-1295 without DAC Works
GHRH receptor
The peptide is designed to stimulate pituitary GHRH receptors.
CJC-1295 without DAC Human Trials and FDA Status
Current status · verified September 15, 2026
Research-use listing; not FDA approved
- No dedicated published human protocol trial of Mod GRF(1-29) was identified.
- Human CJC-1295 Phase 1 studies tested the DAC-bearing compound, not this short-acting form.
- Animal receptor and pharmacology work provides indirect context only.
- Community schedules are extrapolated from GHRH physiology and anecdotal use.
- No approved indication or active clinical-development pathway was identified.
Who Should Avoid CJC-1295 without DAC?
This is an evidence-gap and precaution list, not an approved prescribing label.
Active or recent cancer
GH and IGF-1 pathway concern
Uncontrolled glucose disorder
Metabolic effects are uncertain
Pituitary or acromegaly disorder
Pathway-specific concern
Pregnancy or breastfeeding
No safety data
Known ingredient sensitivity
Potential allergic risk
Tested athletes
GH-releasing factors are prohibited
CJC-1295 without DAC Side Effects, Risks and Safety
Flushing or warmthCommunity reported
Important limitation: No controlled incidence.
HeadacheCommunity reported
Important limitation: Often described as transient.
Injection-site irritationCommunity reported
Important limitation: No controlled incidence.
Water retention or tinglingCommunity reported
Important limitation: Potential GH-axis effects.
Glucose effectsUnknown
Important limitation: No direct long-term study.
Multi-year safetyNot established
Important limitation: No direct human dataset.
CJC-1295 without DAC Timeline and Monitoring
Four to twelve weeks
Community cycle range, not a clinical study duration.
Two to six weeks off
Community rest convention, not validated.
Monitoring
No validated biomarker panel or stopping rule exists for this form.
CJC-1295 without DAC Benefits and Results: What the Evidence Shows
| Claim | Evidence level | What research shows | Important limitation |
|---|---|---|---|
| Pulsatile GH release | Mechanistic hypothesis | GHRH receptor activity | Direct human data absent |
| IGF-1 increase | Not established for this form | Extrapolated from DAC research | Do not transfer |
| Body composition | Not established | Community claim | No trial |
| Sleep or recovery | Not established | Anecdotal | No controlled evidence |
CJC-1295 without DAC Storage and Handling
Unreconstituted vial
No independently verified product-specific stability duration was identified.
Prepared vial
Community refrigerated-use windows are not validated stability studies.
Freeze-thaw
Product-specific effects are not established.
Appearance
Visual inspection cannot establish purity or sterility.
CJC-1295 without DAC Troubleshooting
A multi-day half-life is shown
That belongs to the DAC form, not Mod GRF(1-29).
Units look wrong
Recheck vial mg, liquid mL, target mg, and U-100 conversion.
A DAC trial is cited
Label it related-compound context only.
Product testing is pending
Do not describe the current batch as verified.
A scheduled amount is missed
No validated missed-dose procedure exists.
CJC-1295 without DAC Comparisons
| Compound | Class or mechanism | Evidence | FDA status |
|---|---|---|---|
| CJC-1295 without DAC | Short-acting GHRH analogue | No direct protocol-scale human trial | Not approved |
| CJC-1295 with DAC | Long-acting albumin-binding GHRH analogue | Early human PK/PD | Not approved |
| Tesamorelin | GHRH analogue | Approved narrow indication | Different molecule |
| Ipamorelin | Ghrelin-receptor agonist | Different receptor | Not approved |
CJC-1295 without DAC Frequently Asked Questions
What is CJC-1295 without DAC?
The short-acting GHRH analogue Mod GRF(1-29).
Is it the same as CJC-1295 with DAC?
No.
What half-life is reported?
About 30 minutes, but dedicated human PK is not established.
Does it have direct human trials?
No dedicated protocol-scale human trial was identified.
Are the daily amounts validated?
No.
Is it FDA approved?
No.
Can DAC findings be transferred?
No.
Is fasted timing proven?
No; it is source/community reported.
Is a rest period established?
No.
What does the calculator do?
It performs concentration and volume arithmetic only.
Sources and Research
Coverage source
1. CJC-1295 without DAC protocol coverage source
Community schedule and evidence boundary.
Open direct sourceRelated-compound human research
2. CJC-1295 human pharmacology
DAC-bearing molecule only; related-compound context, not evidence for no-DAC form.
Open direct sourceRelated-compound research
3. CJC-1295 albumin-bioconjugate characterization
Preclinical characterization of the DAC molecule; not a no-DAC protocol trial.
Open direct sourceMissing information flagged for review
- Direct human protocol trial: Not established
- Human pharmacokinetics: Not established
- Validated dose and frequency: Not established
- Clinical outcomes: Not established
- Validated cycle and rest period: Not established
- Product-specific stability: Not established
- Long-term safety and interactions: Not established